FDA approves new autoinjector for cholesterol drug Lerodalcibep-liga, expanding its cardiovascular risk reduction indication.

The FDA has approved a new autoinjector for the PCSK9 inhibitor lerodalcibep-liga (Lerochol), simplifying its monthly administration. The drug's label was also updated to reflect its ability to reduce cardiovascular risk by lowering LDL-C. This development offers a more convenient treatment option for hypercholesterolemia patients, potentially improving adherence and broader access to cardiovascular risk management.